Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Title
Intervention Indication Therapeutic Area Year Actions
Teclistamab for previously treated relapsed or refractory multiple myeloma Teclistamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Tazemetostat for treating relapsed or refractory
follicular lymphoma after two therapies
Tazemetostat (E7438;EPZ-6438;Tazverik) Follicular lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Talquetamab for previously treated relapsed or refractory multiple myeloma Talquetamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm Tagraxofusp (Elzonris; SL-401) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Haematological Cancer and Lymphomas 2018 View  |  Download
Tafasitamab with lenalidomide as add-on therapy for previously treated follicular lymphoma or marginal zone lymphoma Lenalidomide (Revlimid) , Tafasitamab (MOR208; Monjuvi) Follicular lymphoma , Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2023 View  |  Download
Tafasitamab in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma Tafasitamab (MOR208; Monjuvi) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Tabelecleucel for Epstein-Barr Virus-associated lymphoproliferative disease following solid organ transplant Tabelecleucel (Tab-cel; ATA129) Post-transplant lymphoproliferative disease (PTLD) Haematological Cancer and Lymphomas 2019 View  |  Download
Synthetic hypericin (SGX301; VIMRxyn) for cutaneous T‐cell lymphoma, unspecified Hypericin (SGX301; HBP-347) Cutaneous T-cell lymphoma (CTCL) Haematological Cancer and Lymphomas 2017 View  |  Download
Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed and/or refractory multiple myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) , Subcutaneous isatuximab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2023 View  |  Download
Selinexor in combination with low-dose dexamethasone for penta-refractory multiple myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Selinexor (KPT-330; Xpovio) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications